BioSpace News Archive

NurExone Biologic Inc., a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, has released its financial results for 2022, the first since it became public last June.

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) announces the addition of four new internationally recognized thought leaders to its Scientific Advisory Board (“SAB”), effective immediately.

AIM ImmunoTech Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — announced Nancy K. Bryan as the newest member of its Board of Directors.

Agenus Inc. announced that its Board of Directors has declared a dividend of 5 million shares of common stock of its subsidiary, MiNK Therapeutics, Inc., to shareholders of Agenus as of April 17, 2023.

Rakovina Therapeutics Inc. announced the engagement of Red Cloud Securities and Proactive Investors North America Inc. as part of the Company’s evolving strategy to improve trading liquidity and increase general market awareness of the Company and its next-generation cancer therapy development pipeline.

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the publication of clinical trial data demonstrating the potential of Vaxxas’ high-density microarray patch (HD-MAP) to effectively deliver vaccine payloads when used either by trained professionals or individual self-administration.

EMIT IMAGING, Inc. is pleased to announce the appointment of Dr. Matthew Silva as the company’s new Chief Executive Officer.

American Regent announces the launch of sulfite-free Epinephrine Injection, USP.

Flare Therapeutics Inc. announced the appointment of Michael L. Meyers, M.D., Ph.D. as Chief Medical Officer, as well as the promotions of Daphne Karydas, formerly Chief Operating Officer and Chief Financial Officer, to President and Chief Financial Officer and Michaela Bowden, Ph.D., formerly Senior Vice President, Biology & Translation, to Chief Development Officer.

Cognito Therapeutics, today announced neuroimaging results evaluating the effects of the company’s non-invasive neuromodulation medical device, which delivers proprietary gamma frequency light and sound stimulation in participants with Alzheimer’s disease (AD).